|
PDCD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.61299995371911E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30109999996186E-07 |
| Normal-vs-Stage2 |
2.180500E-04 |
| Normal-vs-Stage3 |
2.3257999970383E-09 |
| Normal-vs-Stage4 |
2.55100000001729E-06 |
| Stage1-vs-Stage2 |
5.554800E-01 |
| Stage1-vs-Stage3 |
5.533500E-02 |
| Stage1-vs-Stage4 |
7.575600E-01 |
| Stage2-vs-Stage3 |
6.456200E-01 |
| Stage2-vs-Stage4 |
7.149200E-01 |
| Stage3-vs-Stage4 |
2.464200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.83400003254064E-09 |
| Normal-vs-AfricanAmerican |
1.590490E-02 |
| Normal-vs-Asian |
6.553700E-04 |
| Caucasian-vs-AfricanAmerican |
2.230800E-01 |
| Caucasian-vs-Asian |
3.411200E-01 |
| AfricanAmerican-vs-Asian |
6.830400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.69409999975601E-07 |
| Normal-vs-Female |
1.16030000052447E-08 |
| Male-vs-Female |
9.442200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.97989999961968E-07 |
| Normal-vs-Age(41-60Yrs) |
6.08370000043656E-07 |
| Normal-vs-Age(61-80Yrs) |
2.92199997531384E-09 |
| Normal-vs-Age(81-100Yrs) |
2.785700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.511200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.738100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.348800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.258400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.536400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.901200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.321700E-03 |
| Classical-VS-Follicular |
1.127630E-02 |
| Classical-VS-Other |
9.143600E-01 |
| Classical-VS-Normal |
6.25029999978821E-07 |
| Tall-VS-Follicular |
6.198200E-01 |
| Tall-VS-Other |
1.405170E-01 |
| Tall-VS-Normal |
1.86319999984086E-07 |
| Follicular-VS-Other |
3.873600E-01 |
| Follicular-VS-Normal |
4.43310000042274E-07 |
| Other-VS-Normal |
1.035200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.41869999970012E-07 |
| Normal-vs-N1 |
3.96879999997601E-06 |
| N0-vs-N1 |
8.505400E-01 |
|
|
